Background

Primary brain tumors account for up to 2% of all malignancies. Of these, glioblastoma multiforme (GBM) is the most common. GBM is one of the primary tumors of the central nervous system with a very high degree of malignancy – IV according to the classification of the WHO. The survival time from diagnosis in most patients is only a dozen or so months, and the median survival is about 12 months. Only 3–8% of patients live longer than 3 years.

Aim of the study

The aim of the study is to indicate the latest treatment options for glioblastoma multiforme.

Material and methods

English-language scientific literature from 2012 - 2022 from databases such as PubMed, SCOPUS, Web of Science, Google Scholar was reviewed. Searches were conducted according to keywords: GBM, glioblastoma multiforme, immunotherapy, chemotherapy. 25 items of literature were qualified for analysis.

Results and conclusions:

Despite advances in science, glioblastoma is still not a curable disease. Large amounts are placed in molecular carriers that can cross the blood-brain barrier and reach the tumor directly. Immunotherapy is becoming an effective alternative to non-specific chemotherapy, which is also associated with fewer systemic side effects. The results of studies on the use of CAR-T therapy in the treatment of solid tumors are becoming more and more promising. What is more, nursing staff play an important role in the care of a patient with GBM.